5 / 18
Page 29
Biochemistry & Molecular Biology Journal
ISSN: 2471-8084
Internat i ona l Conference on
Biotechnology, Biomarkers
& Systems Biology
M a r c h 0 4 - 0 5 , 2 0 1 9
Am s t e r d a m , N e t h e r l a n d s
Biotechnology, Biomarkers & Systems Biology 2019
Background:
In 2017, a program on patient blood management was posted to
the National External Quality Assurance Scheme conference for hemostasis
and thrombosis [1]. This subsequent coagulum-OMIC framework is a standard
for predictive value within personalized and regeneration medicine. An OMIC
model is a foresight by the author of this program to achieve OMIC flow [View
Fig. 1.]. This model sustains the success of Coagulum-OMICS when supported
with the ISO 9000 series. [2] [3] [4].
Study:
ISO 9001 and 9004 are powerful tools to identify and define good
practice in an OMIC model. ISO 9001 is a process based standard and an
ideal standard for OMIC interfaces. The greater challenge in haemostasis
and thrombosis is the end to end process involves several parts of healthcare
under different clinical management or vendor arrangements. The flexibility of
ISO 9004 makes it an ideal tool to access Coagulum-OMICs and sustain the
success of personalised and regeneration medicine.
Program Development:
A strategy for Research, Family, Organ and Acute
Coagulum-OMICs commences biphasic policy objectives for genomics as a
primary care with viscoelastic science, coagulum and platelet proteomics [Fig.
2]. Model OMIC development, resources, performance review and innovation,
become learned. OMIC teams self-assess the Coagulum-OMICs to identify
conformity with the model. Regional committees are supported by a joint
working group on quality assurance to manage or improve OMICs
Conclusion:
A model for blood coagulum-OMICs is a benchmark to sustain
excellence in the future of biological systems. The agility of Coagulum-OMICS
to transverse primary and secondary care with genomic [pharma] pre-exams
and viscoelastic or proteomic exams makes it a perfect learning initiative, self-
assessment tool and governance program. The caveat is a need for expertise
to sustain the success of coagulum-OMICs, in situ, with personalised and
regeneration medicine.
Biography
James Henry completed his Master of Science (Upper Merit)
in 2009 from Middlesex University U.Kin Molecular Pathology.
Also he completed his Master of Science (Distinct) in 2014
fromUniversity of Greenwich U.K in Patient Blood Management
Quality Systems. In 2014 a Patient BloodManagement program
was overseen by a U.K national governance representative,
sponsored by an anesthetic lead and edited by an MHRA
inspector who stated “this program is suitable for the NHS”. In
2017 that program was posted to the National External Quality
Assurance Scheme and then to the British Blood Transfusion
Society. In 2018, ISO published the “Quality of an organization —
Guidance to achieve sustained success”. The author of “Blood
Coagulum-OMICs” has developed a model for hemostasis and
thrombosis genomic pre-exams and a viscoelastic & proteomic
examination to improve predictive value in personalized and
regeneration medicine.
jameshenrybms@hotmail.comPersonalized and Regeneration Medicine require
a Coagulum-OMICs Model
James Andrew Henry
Atlantis BMS Limited, UK
James Andrew Henry, Biochem Mol biol J 2019, Volume:5
DOI: 10.21767/2471-8084-C1-023